Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Restylane SubQ Lidocaine is an injectable dermal filler developed by Galderma (through its subsidiary Q-Med AB) designed for deep subcutaneous or supraperiosteal injection to restore and contour facial features, including the midface, cheeks, chin, and jawline. The formulation utilizes Non-Animal Stabilized Hyaluronic Acid (NASHA) technology, providing a cross-linked hyaluronic acid gel (20 mg/ml) with a large particle size for significant lifting capacity and structural support. It also contains 0.3% lidocaine hydrochloride (3 mg/ml) to act as a local anesthetic, improving patient comfort during the injection process. The primary mechanism involves the hyaluronic acid acting as a volumizing agent within the extracellular matrix by attracting and binding water molecules to correct facial volume loss and wrinkles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Restylane SubQ Lidocaine.